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OUTCOMES
End-Stage Renal Disease in Familial Amyloidosis ATTR Val30Met: A
Definitive Indication to Combined Liver-Kidney Transplantation
L. Lobato, A. Ventura, I. Beira˜o, H.P. Miranda, R. Seca, A.C. Henriques, M. Teixeira, A.M. Sarmento, and
M.C. Pereira
AUTOSOMAL dominant amyloidoses characterized sofar are most commonly associated with transthyretin
(TTR), a plasma protein synthesized by the liver.1 The
single gene for TTR2 is located on human chromosome 18;
more than 70 TTR mutations have been documented.3
The most common type of hereditary amyloidosis is
familial amyloid polyneuropathy type I (FAP, Portuguese
type), a neuropathic form associated with a substitution of
methionine for valine at position 30 of the TTR gene, TTR
Val30Met.4 The largest number of patients and families
with this mutation has been identified in Portugal, but now
it has been recognized worldwide.3
FAP in Portugal usually begins in the third or fourth
decade of life with death occuring about 11 years later.5 The
clinical disease usually starts as a sensory neuropathy in the
lower extremities, but autonomic and gastrointestinal fea-
tures may occur early. Motor neuropathy usually manifests
itself later with cardiac conduction disturbances frequently
leading to the need for artificial pacing. Vitreous deposits of
amyloid have been reported, most particularly in Swedish
families.6 Cachexia has been described as a significant
factor in mortality.3 Orthotopic liver transplantation (OLT)
is widely recommended for patients affected by FAP; it is
recognized as the only specific treatment for this disease.7
Virtually all TTR is produced by the liver, and, therefore,
OLT halts the supply of variant amyloidogenic TTR
(ATTR).
Amyloid proteins have different organ specificity, leading
to variations in clinical features. Classically, nephropathic
and nonneuropathic autosomal dominant amyloidoses are
associated with apolipoprotein A-I and A-II, fibrinogen
A-chain, and lysozyme.8 Renal amyloidosis also has been
described in FAP.9 In Portugal, approximately one third of
FAP patients have clinical renal features with varying
degrees of proteinuria and renal failure. The progression to
end-stage renal disease (ESRD) occurs in 10% of Portu-
guese patients, more than 10 years after the onset of
symptoms (Lobato et al, unpublished data). Although dial-
ysis may prolong life, it does not prevent the progression of
systemic amyloid involvement; death occurred, on average,
at 22 months after renal replacement therapy. The cause
was infection in one half of the patients (Lobato et al,
unpublished data).
The first successful renal transplantation in a patient with
renal amyloidosis was reported in 1968,10 but until now this
treatment has been associated with poor graft and patient
survival.11 Most published series concerning renal trans-
plantation in amyloidosis deal with familial Mediterranean
fever or other forms of reactive amyloidosis (AA type).12
The results of kidney transplantation in ATTR have not
been described.
In patients with FAP undergoing dialysis, the potential
advantages of simultaneous liver-kidney transplantation
instead of isolated kidney transplantation are to avoid the
progression of systemic manifestations and the recurrence
of renal amyloidosis. The obstacles to renal transplantation
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in these patients are the presence of postural hypotension,
advanced motor deficits, neurogenic bladder, and decubitus
ulcers related to the long duration of the disease.
We report here on two Portuguese patients with familial
amyloid neuropathy, TTR Val30Met, who underwent com-
bined liver-kidney transplantation for ESRD caused by
amyloidosis. Both patients have been followed up for more
than 18 months after surgery. We analyzed their clinical
course and main complications after the procedure.
PATIENTS AND METHODS
Selection of Patients
The reported patients were selected from a cohort of 22 subjects
with FAP, all carrying the TTR Val30Met mutation and receiving
dialysis during 1999. The two patients had family history of FAP,
TTR amyloidosis in renal biopsy specimens shown by congophilic
deposits with green birefringence under polarized light, and posi-
tive immunolabelling by anti-TTR monoclonal antibodies. Our
conditions for combined liver-kidney transplantation were as fol-
lows: (1) ability to walk without aid or no more than one crutch to
walk; (2) absence of permanent bladder catheter, (3) absence of
neurogenic or decubitus nonhealing ulcers; (4) absence of dialysis-
related syncope or persistent vomiting due to autonomic neurop-
athy; and (5) general conditions suitable for kidney and liver
transplantation.
Immunosuppressive Protocol
Induction therapy included rabbit antithymocyte globulin (ATG; 3
mg/kg/d), cyclosporine (6 mg/kg/d), azathioprine (2 mg/kg/d), and
prednisolone (500 mg intravenously followed by tapering doses
until 0.5 mg/kg/d oral at day 6 after transplantation). Cyclosporine
was adjusted to obtain trough blood levels between 150 ng/mL and
250 ng/mL (whole-blood, fluorescent polarization immunoassay)
for the first 8 weeks. The long-term immunosuppressive regimen
included cyclosporine maintaining trough blood levels between 100
and 150 ng/mL (using the same measurement technique), azathio-
prine (0.5–1 mg/kg/d), and prednisolone (10 mg/d during the first 2
years, 5 mg/d thereafter).
Antimicrobial Prophylaxis
Immediate posttransplantation antimicrobial prophylaxis consisted
of teicoplanine (6 mg/kg/d every 72 hours for 1 week), aztreonam
(500 mg every 8 hours for 3 days), trimethropim (160 mg) and
sulfamethoxazol (800 mg) every 24 hours, and nystatin mouth wash
for 6 months. Antiviral therapy with ganciclovir 500 mg every 12
hours for 3 months was used to prevent cytomegalovirus infection.
One year after transplantation, we started antimicrobial prophy-
laxis for urinary tract infection (UTI) with oral first generation
cephalosporin or amoxacillin every 24 hours.
Clinical Procedures and Evaluation
The patients were offered combined liver and kidney transplanta-
tion using a single cadaveric donor who was ABO blood group
compatible of 0 HLA match and with a negative crossmatch. A
ureteral stent was placed at the time of renal transplantation and
removed between the second and the third week after surgery. Our
policy was to remove the urinary catheter at 1 or 2 weeks after
removal of the ureteral stent, to avoid precocious urinary tract
obstruction due to a neurogenic bladder in the presence of a stent.
Patients were discharged from the hospital when they were able
to walk (alone or with aid) and to feed themselves. Daily physio-
therapy was initiated 1 week after surgery and carried out during
the first hospital stay; physiotherapy was maintained twice per week
in the first 3 months after transplantation.
An accurate examination of the skin was performed routinely
after transplantation. Superficial wounds, particularly in the ex-
tremities, were treated with topical clorhexidine and fusidic acid
adjunctive.
Patients were categorized according to a modified disability
scoring system13 before transplantation and at the end of follow-up:
score I, sensory disturbances in the extremities but preserved
walking capacity; score II, difficulties walking without the need for
a walking stick; score IIIA, one walking stick or one crutch required
for walking; score IIIB, two walking sticks or crutches required; and
score IV, patients in a wheelchair or bed-confined.
The symptoms of autonomic neuropathy were systematically
questioned. Measurements of blood pressure and pulse rate in the
recumbent and standing positions were recorded on each visit.
Urinalysis with screening of proteinuria and bacteriuria were
assessed at all visits. Criteria for antimicrobial therapy in UTIs
included all positive cultures with more than 105 bacterial colonies
during the first 6 months, and symptomatic bacteriuria thereafter
(pyuria and fever). One single urethral catheterization was recom-
mended in case of a UTI with urinary residue.
Evaluation of amyloid involvement within the vitreous humor of
the eye and two-dimensional and M-mode echocardiography were
performed at least 6 months before transplantation and during the
follow-up.
RESULTS
Patients’ Characteristics
Patient 1. Patient 1 was a 44-year-old woman when first
evaluated in 1994 and is of Portuguese ancestry. She had
sinus bradycardia, hypertension, and nephrotic syndrome.
Sensory neuropathy of the lower limbs and constipation
began 1 and 2 years later, respectively. Renal biopsy
specimen revealed extensive TTR amyloidosis. She had a
strong family history of FAP (proved TTR Val30Met) and
renal failure. Two years after presentation, a cardiac pace-
maker was needed. Recurrent UTI and urinary inconti-
nence were present since 1996; postvoid residual urine was
estimated at 100 mL. The renal impairment progressed to
ESRD and the patient commenced hemodialysis in Decem-
ber 1997. She became progressively fatigued, with alternat-
ing diarrhea-constipation and nocturnal fecal incontinence.
Weight loss was estimated at 2 kg. Before transplantation
she was score I for motor neuropathy, and, by this time, she
showed palsy of dorsiflexion of the toes. Combined liver-
kidney transplantation was performed in January 2000.
Patient 2. Patient 2, a man of Portuguese origin, was
found to have sexual impotence at 32 years of age (1986).
Inquiries revealed a younger sister with a peripheral neu-
ropathy; TTR Val30Met mutation was identified in both.
One year later he admitted constipation and disturbed
micturition. Hyposthesia of the lower limbs began in 1991
and later diarrhea; when he was 37 years old. Difficulty in
walking slowly progressed until one crutch was necessary in
1998 at which time he experienced daily and nocturnal
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diarrhea. Proteinuria was detected during the year 6 of the
disease, but by year 10 he had hypertension, urinary incon-
tinence, nephrotic syndrome, and renal failure. Renal bi-
opsy specimen showed vascular and mesangial amyloid
deposits (ATTR) with advanced glomerulosclerosis. He
reached end-stage renal failure and initiated hemodialysis
in October 1999. Insertion of a cardiac pacemaker in the
presence of first-degree atrioventricular block was per-
formed in preparation for transplantation. Intermittent
self-catheterization for optimal bladder drainage was initi-
ated after 2 episodes of pyocystis in 2000; no urinary reflux
was shown. Three months after dialysis was initiated, he
developed a crisis of vomiting. The weight loss since disease
onset was 9 kg (17%). His score for motor neuropathy was
IIIA. He underwent simultaneous liver-kidney transplanta-
tion in October 2000.
Table 1 summarizes the clinical characteristics and out-
comes after combined liver-kidney transplantation.
Posttransplantation Management and Morbidity
The early postoperative period was uneventful; the patients
were admitted to the intensive care unit and discharged
after 48 hours. Perioperative blood transfusions were 8 and
2 u for patients 1 and 2, respectively. The allografts had
immediate function, although one short hemodialysis ses-
sion was necessary to correct severe metabolic acidosis in
patient 1. The native livers were found to be normal with
scarce vascular amyloid deposits.
Both patients developed septicemia in the first week after
transplantation (pulmonary and central catheter related)
and urinary Candidiasis in the second week. No special
problems were related to the management of surgical
wounds. There were no episodes of rejection of either the
renal or liver grafts. The patients were discharged with good
graft function at 4 and 3 weeks after transplantation,
respectively.
Patient 1 presented with a skin infection of the right foot
after an accidental water burn in the second month after
transplantation, which required surgical debridement, anti-
biotics, and skin graft. Patient 2 developed a maleolar
neurogenic ulcer during the first hospital admission, which
completely healed with local care.
The postvoid residual urine volume was evaluated after
urinary catheter removal; intermittent catheterization was
performed if that volume exceeded 150 mL, or when
ureteral dilation or hydronephrosis of the renal graft was
present. Both patients developed recurrent UTI. There
were four hospital readmissions, all caused by infections
(UTI and skin), exclusively during the first posttransplan-
tation year. The antimicrobial prophylaxis for UTI de-
creased the episodes of bacteruria and associated febrile
episodes did not recur. Episodes of low blood cyclosporine
levels were found to be related to transient uncontrollable
diarrhea. We did not observe posttransplantation hyperten-
sion or hyperlipidemia. Treatment with human recombi-
nant erythropoietin was suspended at 2.5 months after
transplantation.
FAP Manifestations After Combined Liver-Kidney
Transplantation
The clinical motor score and sensory deficits remained
unchanged. Transient postural hypotension appeared con-
comitant with some UTI episodes during the first year after
transplantation. We verified a progressive amelioration of
bladder emptying; at the end of follow-up the postvoid
urine volume was 50 mL. At the last observation, the
patients continued to experience alternating diarrhea and
constipation. A vomiting crisis appeared in patient 2 in the
presence of a UTI. Both patients gained weight, 8 kg for
patient 1 and 4 kg for patient 2. An active life was possible
for patient 1, although with fatigue. Patient 2 ameliorated
his social life and tolerance to effort.
Echocardiographic studies, before transplantation and
after 24 and 14 months of follow-up, for patients 1 and 2
respectively, are detailed in Table 2. A “speckled” appear-
ance of the myocardial wall was not observed and diastolic
left ventricular function was considered normal. None of
the patients showed vitreous opacities, glaucoma, or other
ocular complications before or after transplantation.
Table 1. Clinical Characteristics of Patients With FAP-I Who
Underwent LKT
Patient 1 Patient 2
Age at LKT (y) 50 46
Duration of disease at LKT (y) 6 14
Time on dialysis before LKT (mo) 25 12
Serum creatinine at 1 year after LKT (mg/dL) 1.4 1.0
Serum creatinine at end of follow-up (mg/dL) 1.3 1.3
Aspartate aminotransferase/serum alkaline
phosphatase at end of follow-up (U/L)
35/31 29/67
Posttransplantation proteinuria Absent Absent
Hemoglobin at end of follow-up (g/dL) 11.8 14.4
Serum albumin before/after LKT (g/dL) 3.4/3.5 3.6/3.7
Hospital admissions related with infections 3 1
Time of follow-up after LKT (mo) 27 18
Outcome Alive Alive
Abbreviation: LKT, combined liver-kidney transplantation.
Table 2. Echocardiographic Measurements Before and After
LKT
Patient 1
Before
LKT/After
24 mo
Patient 2
Before
LKT/After
14 mo
Left ventricular end-diastolic diameter
(N  54 mm)
55/55 52/50
Posterior left ventricular wall thickness
(N  11 mm)
10/13 14/12
Interventricular septum (N  11 mm) 12/13 13/13
Aortic root dimension (N  39 mm) 24/27 34/37
Left atrial dimension (N  38 mm) 44/45 49/48
Abbreviations: LKT, combined liver-kidney transplantation; N, normal value in
adults.
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DISCUSSION
ATTR Val30Met With ESRD is an Indication for Combined
Liver-Kidney Transplantation
We have shown that simultaneous liver-kidney transplanta-
tion is useful for treatment of ESRD associated with the
TTR Val30Met mutation. Technical problems during the
liver or kidney transplantation have not been observed,
neither have they required a long stay in the intensive care
unit.
In general, patients with amyloidosis undergoing renal
transplantation tolerate complications poorly and are at
high risk of dying within the first 3 months.14 Deaths after
isolated liver transplantation in FAP often occurred within
6 months after surgery (57%).15 Therefore, although our
follow-up did not exceed 27 and 18 months, respectively, an
important finding was the absence of early death, encour-
aging us to continue this therapy. Combined liver-kidney
transplantation has been used for diseases that lead to
end-stage failure of both organs, or in inherited metabolic
disorders in which the primary defect is hepatic and leads to
renal damage.16 This approach to systemic hereditary amy-
loidosis was detailed in two patients but both also had
progressive liver dysfunction: one with fibrinogen -chain
Glu526Val mutation, and another with apolipoprotein AI
Gly26Arg mutation.17,18 In familial amyloidosis related to
TTR Val30Met mutation, liver amyloid deposits are scarce
and progressive hepatic failure absent; OLT was done only
to reduce the supply of amyloid fibrils.
In both patients, there was immediate graft function and
an absence of rejection episodes. Abdominal pain and
muscle weakness after renal transplantation have been
reported in patients with amyloidosis, associated with high
doses of cyclosporine.19 Induction therapy with ATG and
long-term triple immunosuppressive regimen provide an
option that allows early low cyclosporine doses and dimin-
ishing risks of rejection.
Early Posttransplantation Complications are Urinary and
Skin Infections
Autonomic neuropathy causing urinary retention or incon-
tinence represents an additional problem in kidney trans-
plantation. The neurogenic bladder may exert deleterious
effects on the renal graft. In patients with FAP with isolated
liver transplantation, the origin of lethal septicemia was
urinary in 71%, and urinary incontinence was associated
with higher transplant mortality.15 Our policy of systematic
evaluation of bacteriuria, intermittent self-catheterization
in patients with incomplete voiding, surveillance of skin
wounds, and long-term antimicrobial prophylaxis may ex-
plain the low number of hospital admissions related to
infections. Urinary Candidiasis was observed early in the
posttransplantation period, therefore prompt removal of
ureteral stents is advisable. On the other hand, no other
sources of infection were observed except the urinary tract
and the skin.
Potential Benefits of Combined Liver-Kidney
Transplantation in FAP
In patients with ESRD and FAP who underwent combined
liver-kidney transplantation, we expect neither recurrence
of amyloidosis in kidney graft nor deterioration of neurop-
athy. Although kidney transplantation has been described
for severe amyloid TTR nephropathy,15 the outcome of the
renal transplantation was not specified.
The recurrence rate of amyloidosis in the renal allograft,
based on evidence from biopsy specimens, may reach 26%
in patients who survive beyond 12 months after transplan-
tation.12 The recurrence of renal ATTR after liver-kidney
transplantation in FAP is not expected: several reports
consistently confirm a rapid and steady decrease of circu-
lating mutated TTR in the serum after liver transplanta-
tion.12,20 Meanwhile, the progression of cardiomyopathy
after liver transplantation among patients with FAP, TTR
Val30Met, has been attributed to deposition of wild-type
TTR-amyloid.21 The amyloid fibrils in the hearts of patients
with FAP (including ATTR Val30Met), which died of
terminal cardiac failure after liver transplantation, were
composed of wild-type TTR and variant TTR at a ratio of
1:1.22 The kidney allograft, unlike the heart, is a genetically
different organ without previous deposits, and thus recur-
rence of amyloidosis seems less probable.
In our experience, 50% of patients with FAP on regular
hemodialysis die during the first year of therapy, and
neuropathy progresses in all subjects (unpublished data). In
ATTR liver-kidney recipients no deterioration of the motor
deficit has been observed at present. Autonomic nervous
dysfunction is a well-recognized complication of ESRD,
whatever the etiology. A recent study failed to show com-
plete normalization of the autonomic nervous system test-
ing after kidney transplantation; however, there was a
tendency to improve with the longevity of normal renal
function.23 Then, in FAP, the renal transplantation may
represent an extra benefit for dysautonomy.
The long-term prognosis of patients with renal amyloid-
osis would appear to be dependent on the presence of
cardiac amyloidosis and amyloidosis of the adrenals.12 In
both patients, echocardiographic findings before transplan-
tation showed abnormal values in the left atrial dimension
and in the interventricular septal thickness whereas signs of
cardiomyopathy were present, the disorder did not repre-
sent a problem during the early posttransplantation period.
In one patient, the left atrial dimension was increased and
the thickness of the septal and left ventricular dimension
increased after transplantation, as was previously described
in the Swedish study with isolated OLT.21 Curiously, that
was the patient with a shorter duration of disease and a
lower score for motor neuropathy. More follow-up will be
necessary to clarify whether those findings have a deleteri-
ous impact on renal graft function or patient survival.
In conclusion, the available data in selected patients,
suggest that combined liver-kidney transplantation is rec-
ommended for ESRD in FAP TTR Val30Met. Early treat-
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ment of UTI and skin infections after transplantation is
mandatory to diminish early mortality. Autonomic dysfunc-
tion of the bladder represents an additional problem, but
does not contraindicate transplantation. Recurrence of
amyloidosis in the renal graft is not expected.
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